PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way many expected. Complex patent webs have kept some approved biosimilars off the market for years, as has been the case for potential lower-cost rivals to AbbVie’s Humira and Amgen’s Enbrel. Contracting and pricing strategies for branded drugs have also prevented some other biosimilars from making a bigger dent in the market.

Unlike with generic drugs, pharmacists haven’t been authorized to directly substitute earlier biosimilars when they receive a prescription. Physicians, then, are left to request a biosimilar when writing the prescription. Or insurers must dictate that they will only pay for a biosimilar version.

That should finally change with Semglee. Viatris and Biocon’s drug will be the sixth long-acting insulin on the market, offering an alternative not just to Lantus but also to Novo Nordisk insulins like Tresiba and Levemir, although it is not directly substitutable to those two agents. Biosimilars have, on average, launched with initial prices roughly 15% to 35% lower than their branded counterparts, according to an FDA statement.

“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” acting commissioner Janet Woodcock said in the statement.

In order to qualify Semglee as interchangeable, Viatris and Biocon had to demonstrate that there are no differences between the biosimilar and Lantus on safety, purity and potency. The two also had to prove the clinical benefits would be the same and that there would no risks of harm or diminished efficacy if patients switch from Lantus to Semglee.

Long-acting insulins typically are dosed once or twice daily to keep patients’ blood sugar under constant control, but take hours to take effect. For some patients, that is enough to keep from experiencing dangerous elevations in blood sugar, but others need to supplement with shorter-acting insulins at mealtimes to maintain control.

Viatris plans to begin a commercial launch by the end of the year and transition its current Semglee manufacturing lines to the interchangeable product.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40